Vecuronium
As of the edition of 20 October 2026, Vecuronium is a small molecule: marketed, first approved in 1984 (US); acts on CHRNA1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1984
- Kind
- Small molecule
- Brand name
- Norcuron
- First approved
- 30 April 1984 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Organon
- Registered trials
- 10, 0 stopped early
- Disease areas
- Nervous system; Heart and blood vessels; Injuries; Mental health
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHRNA1 | Acetylcholine receptor subunit alpha | P02708 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 1 | 0 |
| Phase 2 | 2 | 1 | 1 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 5 | 3 | 0 | 0 |
| All trials | 10 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Organon | Acquired holder and Earlier holder | 1984 to now |